Every national cancer statistic began as an abstract on a registrar's desk. As early-onset cancer rises, that desk is where the story of American oncology is being written.
Before any headline announced that colorectal cancer was rising in young adults, cancer registrars were already abstracting the cases: the 34-year-old with rectal cancer, the 41-year-old with distal colon disease, the AYA patients showing up in tumor boards where they used to be rare. National surveillance data doesn't fall from the sky — it's built, case by case, by the registry profession. And right now, that data is describing a genuinely different disease population than the one most cancer programs were designed around.
The American Cancer Society's 2026 colorectal cancer statistics report — built, as always, on population data from SEER and the National Program of Cancer Registries — describes a disease moving in two directions at once. Incidence is falling steadily in adults 65 and older, while rising about 3% per year in adults aged 20–49, with rectal and distal colon tumors driving the increase. Rectal cancer alone now accounts for roughly a third of all colorectal diagnoses, up meaningfully from the mid-2000s.
The pattern isn't unique to colorectal disease, and it isn't confined to one demographic — early-onset increases span racial and ethnic groups. Younger patients are diagnosed later, at more advanced stages, with different treatment considerations: fertility preservation, decades of survivorship, workforce and family impacts that a program built around 70-year-old patients was never designed to track.
The only reason anyone can say "early-onset cancer is rising" with confidence is that thousands of credentialed registrars abstracted those cases accurately, staged them correctly, and reported them on time. Surveillance is only as good as abstraction.
Early-onset cases arrive with heavier documentation: more neoadjuvant therapy sequences, more clinical trial enrollment, more genetic and biomarker testing to capture, more multi-modality treatment to follow across years. An abstract for a 38-year-old rectal cancer patient is simply more work than the average abstract was a decade ago — and forward production standards don't care.
With advanced-stage presentation defining the early-onset problem, the registry's staging accuracy and time-to-treatment data become the evidence base for a program's quality initiatives — earlier symptom workup, screening outreach at age 45, navigation for young patients. Those initiatives are exactly what Commission on Cancer programs are expected to build from their own registry data.
Registry teams were already stretched before the demographic shift added complexity. Backlogs compound quietly: a registry that falls behind loses not just compliance standing but the ability to give its cancer committee a current picture of who its patients actually are — at the precise moment that picture is changing fastest.
Cancer is getting younger, and the institutions that respond well will be the ones that see it in their own data first. That makes the registry — often the least visible department in the cancer program — one of the most strategically important. Keep it current, keep it accurate, and it will tell you where oncology is going before anyone else in the building knows.
CODEMED's ODS-C credentialed registrars provide abstraction, case-finding, backlog recovery, and CoC compliance support — clearing backlogs without sacrificing forward production, for over 27 years.
